Certain Medline Inc. (Nasdaq: MDLN) stockholders have commenced a public offering of 60 million Class A common shares, with the company receiving none of the proceeds from the sale. The offering, announced on May 20, is being managed by a consortium of banks including Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan as global coordinators, according to a company press release.
The sellers, which include affiliates of Blackstone Inc., Hellman & Friedman LLC, and the Abu Dhabi Investment Authority, are also granting underwriters a 30-day option to buy up to 9 million additional shares. Medline itself is not selling any stock in the transaction.
The large-scale sale increases the public float of Medline's stock and could create short-term price pressure by signaling that major private equity backers are continuing to reduce their positions. The move follows a six-month period where insiders sold shares worth over $1.6 billion, according to market data.
Despite the heavy insider selling, Wall Street remains broadly positive on Medline. The company holds seven "buy" ratings from analysts who have issued reports in recent months, with a median price target of $50.00. This compares to a recent price movement that saw the stock rise 5.8%, a move attributed to investors looking past near-term margin pressures to the company's strong growth outlook.
The offering provides a significant liquidity event for the private equity sponsors that took Medline public. Investors will now watch the offering's final pricing and subsequent trading to gauge market appetite for the increased supply of shares.
This article is for informational purposes only and does not constitute investment advice.
